Pioglitazone Represents an Effective Therapeutic Target in Preventing Oxidative/Inflammatory Cochlear Damage Induced...

Area of Science:

• Oto-neurology
• Pharmacology
• Cellular Biology

Background:

• Noise-induced hearing loss (NIHL) involves redox imbalance and inflammation in the organ of Corti.
• Thiazolidinediones, like pioglitazone, are known for anti-inflammatory and redox-balancing properties via PPAR activation.
• These receptors are present in cochlear cells, suggesting a potential therapeutic role.

Purpose of the Study:

• To investigate pioglitazone's protective effects against NIHL in Wistar rats.
• To elucidate the underlying anti-inflammatory and antioxidant molecular mechanisms.
• To assess the efficacy of a novel sustained-release inner ear drug delivery system.

Main Methods:

• Wistar rats were subjected to noise exposure (120 dB, 10 kHz, 1 h).
• Pioglitazone was administered intratympanically via a thermogel formulation at various time points post-exposure.
• Auditory function, cell death, NF-κB, IL-1β expression, and oxidative damage markers were assessed.

Main Results:

• Pioglitazone treatment preserved auditory function at mid-high frequencies.
• It significantly reduced cell death in the basal/middle turns of the cochlea.
• Molecular analysis confirmed decreased NF-κB and IL-1β, indicating reduced inflammation and oxidative stress.

Conclusions:

• Intratympanic pioglitazone demonstrates significant protective effects against NIHL.
• The drug acts by mitigating cochlear inflammation and restoring redox balance.
• This presents a potential therapeutic strategy for managing noise-induced hearing damage.